Genica Pharmaceuticals

About Genica Pharmaceuticals

Operator of a reference laboratory dedicated to the development and commercialization of diagnostics and therapeutics for neurological and neurogenetic disorders. Genica offers an extensive selection of testing services and interpretive consultation. The full-service neurology laboratory offers Southern blot, PCR, PFGE, Western blot, biochemical, and ELISA methodologies. The company provides novel, proprietary tests for neurological disorders in nine major areas. For neurological autoimmune diseases, the MAG and GM1 autoantibody tests were introduced to physicians in 1990. In February 1991, Genica began offering autoantibody tests for paraneoplastic syndrome with technology licensed from Sloan-Kettering Cancer Center. In addition to neurogenetic disorders and autoimmune association with peripheral nerve diseases, the company provides state-of-the-art technology for neurological complications of Lyme disease, testing services for the neuromuscular transmission defect known as Myasthenia Gravis and offers the world's first commercially available risk-factor diagnostic for Alzheimer's disease.